Study of Brolucizumab in Adult Patients With Suboptimal Anatomically Controlled Neovascular Age-related Macular Degeneration

PHASE3CompletedINTERVENTIONAL
Enrollment

295

Participants

Timeline

Start Date

December 14, 2020

Primary Completion Date

October 5, 2022

Study Completion Date

May 10, 2023

Conditions
Neovascular Age-Related Macular Degeneration
Interventions
DRUG

RTH258/Brolucizumab

Brolucizumab is a new generation of anti-VEGF (vascular endothelial growth factor). All patients will be treated with brolucizumab 6mg: 3 loading injections (at Screening/Baseline, Week 4 and Week 8), followed by Treat-to-Control regimen up to Week 44/46.

Trial Locations (51)

13015

Novartis Investigative Site, Marseille

13090

Novartis Investigative Site, Aix-en-Provence

14000

Novartis Investigative Site, Caen

14033

Novartis Investigative Site, Caen

17019

Novartis Investigative Site, La Rochelle

21034

Novartis Investigative Site, Dijon

22190

Novartis Investigative Site, Plérin

31059

Novartis Investigative Site, Toulouse

31240

Novartis Investigative Site, Saint-Jean

33000

Novartis Investigative Site, Bordeaux

33076

Novartis Investigative Site, Bordeaux

34000

Novartis Investigative Site, Montpellier

34295

Novartis Investigative Site, Montpellier

34430

Novartis Investigative Site, Saint-Jean-de-Védas

35033

Novartis Investigative Site, Rennes

37000

Novartis Investigative Site, Tours

37540

Novartis Investigative Site, Saint-Cyr-sur-Loire

38000

Novartis Investigative Site, Grenoble

44093

Novartis Investigative Site, Nantes

44300

Novartis Investigative Site, Nantes

44819

Novartis Investigative Site, Saint-Herblain

45200

Novartis Investigative Site, Montargis

49044

Novartis Investigative Site, Angers

50300

Novartis Investigative Site, Saint-Martin-des-Champs

59000

Novartis Investigative Site, Lille

66000

Novartis Investigative Site, Perpignan

67000

Novartis Investigative Site, Strasbourg

68024

Novartis Investigative Site, Colmar

68070

Novartis Investigative Site, Mulhouse

69002

Novartis Investigative Site, Lyon

69275

Novartis Investigative Site, Lyon

69317

Novartis Investigative Site, Lyon

75001

Novartis Investigative Site, Paris

75007

Novartis Investigative Site, Paris

75010

Novartis Investigative Site, Paris

75015

Novartis Investigative Site, Paris

75651

Novartis Investigative Site, Paris

75674

Novartis Investigative Site, Paris

76100

Novartis Investigative Site, Rouen

77000

Novartis Investigative Site, Melun

78157

Novartis Investigative Site, Le Chesnay

82000

Novartis Investigative Site, Montauban

83160

Novartis Investigative Site, La Valette-du-Var

84000

Novartis Investigative Site, Avignon

86000

Novartis Investigative Site, Poitiers

92500

Novartis Investigative Site, Rueil-Malmaison

93009

Novartis Investigative Site, Bobigny

94000

Novartis Investigative Site, Créteil

94300

Novartis Investigative Site, Vincennes

06001

Novartis Investigative Site, Nice

F 13008

Novartis Investigative Site, Marseille

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY